title: Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.
abstract: Human cancers are incredibly diverse with regard to molecular aberrations, dependence on oncogenic signaling pathways, and responses to pharmacological intervention. We wished to assess how cellular dependence on the canonical PI3K vs. MAPK pathways within HER2+ cancers affects responses to combinations of targeted therapies, and biomarkers predictive of their activity. Through an integrative analysis of mechanistic model simulations and in vitro cell line profiling, we designed a six-arm decision tree to stratify treatment of HER2+ cancers using combinations of targeted agents. Activating mutations in the PI3K and MAPK pathways (PIK3CA and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors against HER2 (lapatinib), HER3 (MM-111), AKT (MK-2206), and MEK (GSK-1120212; trametinib), in addition to the standard of care trastuzumab (Herceptin). The strategy used to identify effective combinations and predictive biomarkers in HER2-expressing tumors may be more broadly extendable to other human cancers.
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Kirouac
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lahdenranta
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: J
authors.initials: J
authors.lastname: Du
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: D
authors.initials: D
authors.lastname: Yarar
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Onsum
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: U B
authors.initials: UB
authors.lastname: Nielsen
authors.affiliation: Merrimack Pharmaceuticals Cambridge, Massachusetts, USA.
authors.forename: C F
authors.initials: CF
authors.lastname: McDonagh